Use of letrozole in assisted reproduction: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Letrozole is the third-generation aromatase inhibitor (AI) most widely used in assisted reproduction. AIs induce ovulation by inhibiting estrogen production; the consequent hypoestrogenic state increases GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis. METHODS: A systematic search of the literature was performed for both prospective and retrospective studies. Meta-analyses of randomized clinical trials (RCTs) were performed for three comparisons: letrozole versus clomiphene citrate (CC), letrozole + FSH versus FSH in intrauterine insemination (IUI) and letrozole + FSH versus FSH in IVF. In the absence of RCTs, non-randomized studies were pooled. RESULTS: Nine studies were included in the meta-analysis. Four RCTs compared the overall effect of letrozole with CC in patients with polycystic ovary syndrome. The pooled result was not significant for ovulatory cycles (OR = 1.17; 95% CI 0.66-2.09), or for pregnancy rate per cycle (OR = 1.47; 95% CI 0.73-2.96) or for pregnancy rate per patient (OR = 1.37; 95% CI 0.70-2.71). In three retrospective studies which compared L + FSH with FSH in ovarian stimulation for IUI, the pooled OR was 1.15 (95% CI 0.78-1.71). A final meta-analysis included one RCT and one cohort study that compared letrozole + gonadotrophin versus gonadotrophin alone: the pooled pregnancy rate per patient was not significantly different (OR = 1.40; 95% CI 0.67-2.91). CONCLUSIONS: Letrozole is as effective as other methods of ovulation induction. Further randomized-controlled studies are warranted to define more clearly the efficacy and safety of letrozole in human reproduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Badawy, A., Aal, I. A., & Abulatta, M. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.02.062 · Cited by 162 · cited 8×
“A meta-analysis including the four randomized-controlled studies comparing letrozole and clomiphene was done (Atay et al., 2006; Bayar et al., 2006; Sohrabvand et al., 2006; Badawy et al., 2007).”
BackgroundMethodResultInfluentialRetractedClomiphene citrate for ovulation induction in women with oligo-amenorrhoea
Hughes, E. G., Collins, J. A., & Vandekerckhove, P. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000056 · Cited by 75 · cited 1×
“Moreover, the percentage of ovarian hyperstimulation syndrome and multiple gestations is low (Hughes et al., 2000).”
BackgroundRetractedAmerican Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
Lee, S. J., Schover, L. R., Partridge, A. H., Patrizio, P., Wallace, W. H., Hagerty, K., Beck, L. N., Brennan, L. V., & Oktay, K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5888 · Cited by 2,048 · cited 3×
“%) were not observed.”
BackgroundAndrogens stimulate early stages of follicular growth in the primate ovary
Vendola, K. A., Zhou, J., Adesanya, O. O., Weil, S. J., & Bondy, C. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2081 · Cited by 712 · cited 1×
“The androgens may also increase FSH receptors making women with PCOS exquisitely sensitive to an increase in FSH through exogenous administration of gonadotrophins, and hence the high risk of ovarian hyperstimulation syndrome and multiple ovulation (Vendola et al., 1998).”
BackgroundAndrogen and follicle stimulating hormone interactions in primate ovarian follicle development
Weil, S., Vendola, K., Zhou, J., & Bondy, C. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5929 · Cited by 592
Oktay, K., Buyuk, E., Libertella, N., Akar, M., & Rosenwaks, Z. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.037 · Cited by 528 · cited 2×
“The combined protocol of letrozole and low-dose FSH was evaluated in the study of Oktay et al. (2005).”
BackgroundMethodFormation and early development of follicles in the polycystic ovary
Webber, L., Stubbs, S., Stark, J., Trew, G., Margara, R., Hardy, K., & Franks, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14410-8 · Cited by 522 · cited 1×
“Given that women treated with IAs had temporary accumulation of intraovarian androgens (Webber et al., 2003), it has been postulated that this androgenic intrafollicular environment may improve response to ovarian stimulation in low responders.”
BackgroundMendez, J. E., & Kuerer, H. M. (2005) · The Women s Oncology Review · doi:10.1080/14733400500247512 · Cited by 424
Oktay, K., Hourvitz, A., Sahin, G., Oktem, O., Safro, B., Cil, A., & Bang, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0962 · Cited by 421 · cited 2×
“In a study of the same group published 1 year later (Oktay et al., 2006), Stages I–IIIA breast cancer patients (n 1⁄4 47) received 5 mg/day letrozole and 150–300 IU FSH to cryopreserve embryos or oocytes.”
BackgroundGoswami, S. K. (2004) · Human Reproduction · doi:10.1093/humrep/deh359 · Cited by 372 · cited 2×
“Keywords: androgens; FSH; IVF”
Background
Cited by
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Metadata
- Authors
- Requena, A., Herrero, J., Landeras, J., Navarro, E., Neyro, J. L., Salvador, C., Tur, R., Callejo, J., Checa, M. A., Farre, M., Espinos, J. J., Fabregues, F., Grana-Barcia, M., & Reproductive Endocrinology Interest Group of the Spanish Society of Fertility
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-29
- Volume
- 14
- Issue
- 6
- Pages
- 571-582
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2096067447
- Cited by
- 197
- References
- 60
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.